Click for best price
Insulin Biosimilars Market Size, Share 2023
Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
This report aims to provide a comprehensive presentation of the global market for Insulin Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Insulin Biosimilars. This report contains market size and forecasts of Insulin Biosimilars in global, including the following market information:
Global Insulin Biosimilars Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Insulin Biosimilars Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Insulin Biosimilars companies in 2022 (%)
The global Insulin Biosimilars market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Rapid-Acting Biosimilars Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Insulin Biosimilars include Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Insulin Biosimilars manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Insulin Biosimilars Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Insulin Biosimilars Market Segment Percentages, by Type, 2022 (%)
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars
Global Insulin Biosimilars Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Insulin Biosimilars Market Segment Percentages, by Application, 2022 (%)
Type I Diabetes
Type II Diabetes
Global Insulin Biosimilars Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Insulin Biosimilars Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Insulin Biosimilars revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Insulin Biosimilars revenues share in global market, 2022 (%)
Key companies Insulin Biosimilars sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Insulin Biosimilars sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of Insulin Biosimilars, market overview.
Chapter 2: Global Insulin Biosimilars market size in revenue and volume.
Chapter 3: Detailed analysis of Insulin Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Insulin Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Insulin Biosimilars capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Insulin Biosimilars Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
75 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Insulin Biosimilars Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Insulin Biosimilars Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Insulin Biosimilars Overall Market Size
2.1 Global Insulin Biosimilars Market Size: 2022 VS 2030
2.2 Global Insulin Biosimilars Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Insulin Biosimilars Sales: 2018-2030
3 Company Landscape
3.1 Top Insulin Biosimilars Players in Global Market
3.2 Top Global Insulin Biosimilars Companies Ranked by Revenue
3.3 Global Insulin Biosimilars Revenue by Companies
3.4 Global Insulin Biosimilars Sales by Companies
3.5 Global Insulin Biosimilars Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Insulin Biosimilars Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Insulin Biosimilars Product Type
3.8 Tier 1, Tier 2 and Tier 3 Insulin Biosimilars Players in Global Market
3.8.1 List of Global Tier 1 Insulin Biosimilars Companies
3.8.2 List of Global Tier 2 and Tier 3 Insulin Biosimilars Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Insulin Biosimilars Market Size Markets, 2022 & 2030
4.1.2 Rapid-Acting Biosimilars
4.1.3 Long-Acting Biosimilars
4.1.4 Premixed Biosimilars
4.2 By Type - Global Insulin Biosimilars Revenue & Forecasts
4.2.1 By Type - Global Insulin Biosimilars Revenue, 2018-2023
4.2.2 By Type - Global Insulin Biosimilars Revenue, 2024-2030
4.2.3 By Type - Global Insulin Biosimilars Revenue Market Share, 2018-2030
4.3 By Type - Global Insulin Biosimilars Sales & Forecasts
4.3.1 By Type - Global Insulin Biosimilars Sales, 2018-2023
4.3.2 By Type - Global Insulin Biosimilars Sales, 2024-2030
4.3.3 By Type - Global Insulin Biosimilars Sales Market Share, 2018-2030
4.4 By Type - Global Insulin Biosimilars Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Insulin Biosimilars Market Size, 2022 & 2030
5.1.2 Type I Diabetes
5.1.3 Type II Diabetes
5.2 By Application - Global Insulin Biosimilars Revenue & Forecasts
5.2.1 By Application - Global Insulin Biosimilars Revenue, 2018-2023
5.2.2 By Application - Global Insulin Biosimilars Revenue, 2024-2030
5.2.3 By Application - Global Insulin Biosimilars Revenue Market Share, 2018-2030
5.3 By Application - Global Insulin Biosimilars Sales & Forecasts
5.3.1 By Application - Global Insulin Biosimilars Sales, 2018-2023
5.3.2 By Application - Global Insulin Biosimilars Sales, 2024-2030
5.3.3 By Application - Global Insulin Biosimilars Sales Market Share, 2018-2030
5.4 By Application - Global Insulin Biosimilars Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Insulin Biosimilars Market Size, 2022 & 2030
6.2 By Region - Global Insulin Biosimilars Revenue & Forecasts
6.2.1 By Region - Global Insulin Biosimilars Revenue, 2018-2023
6.2.2 By Region - Global Insulin Biosimilars Revenue, 2024-2030
6.2.3 By Region - Global Insulin Biosimilars Revenue Market Share, 2018-2030
6.3 By Region - Global Insulin Biosimilars Sales & Forecasts
6.3.1 By Region - Global Insulin Biosimilars Sales, 2018-2023
6.3.2 By Region - Global Insulin Biosimilars Sales, 2024-2030
6.3.3 By Region - Global Insulin Biosimilars Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Insulin Biosimilars Revenue, 2018-2030
6.4.2 By Country - North America Insulin Biosimilars Sales, 2018-2030
6.4.3 US Insulin Biosimilars Market Size, 2018-2030
6.4.4 Canada Insulin Biosimilars Market Size, 2018-2030
6.4.5 Mexico Insulin Biosimilars Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Insulin Biosimilars Revenue, 2018-2030
6.5.2 By Country - Europe Insulin Biosimilars Sales, 2018-2030
6.5.3 Germany Insulin Biosimilars Market Size, 2018-2030
6.5.4 France Insulin Biosimilars Market Size, 2018-2030
6.5.5 U.K. Insulin Biosimilars Market Size, 2018-2030
6.5.6 Italy Insulin Biosimilars Market Size, 2018-2030
6.5.7 Russia Insulin Biosimilars Market Size, 2018-2030
6.5.8 Nordic Countries Insulin Biosimilars Market Size, 2018-2030
6.5.9 Benelux Insulin Biosimilars Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Insulin Biosimilars Revenue, 2018-2030
6.6.2 By Region - Asia Insulin Biosimilars Sales, 2018-2030
6.6.3 China Insulin Biosimilars Market Size, 2018-2030
6.6.4 Japan Insulin Biosimilars Market Size, 2018-2030
6.6.5 South Korea Insulin Biosimilars Market Size, 2018-2030
6.6.6 Southeast Asia Insulin Biosimilars Market Size, 2018-2030
6.6.7 India Insulin Biosimilars Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Insulin Biosimilars Revenue, 2018-2030
6.7.2 By Country - South America Insulin Biosimilars Sales, 2018-2030
6.7.3 Brazil Insulin Biosimilars Market Size, 2018-2030
6.7.4 Argentina Insulin Biosimilars Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Insulin Biosimilars Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Insulin Biosimilars Sales, 2018-2030
6.8.3 Turkey Insulin Biosimilars Market Size, 2018-2030
6.8.4 Israel Insulin Biosimilars Market Size, 2018-2030
6.8.5 Saudi Arabia Insulin Biosimilars Market Size, 2018-2030
6.8.6 UAE Insulin Biosimilars Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 Sanofi S.A.
7.1.1 Sanofi S.A. Company Summary
7.1.2 Sanofi S.A. Business Overview
7.1.3 Sanofi S.A. Insulin Biosimilars Major Product Offerings
7.1.4 Sanofi S.A. Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi S.A. Key News & Latest Developments
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Summary
7.2.2 Boehringer Ingelheim Business Overview
7.2.3 Boehringer Ingelheim Insulin Biosimilars Major Product Offerings
7.2.4 Boehringer Ingelheim Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.2.5 Boehringer Ingelheim Key News & Latest Developments
7.3 Eli Lilly & Co.
7.3.1 Eli Lilly & Co. Company Summary
7.3.2 Eli Lilly & Co. Business Overview
7.3.3 Eli Lilly & Co. Insulin Biosimilars Major Product Offerings
7.3.4 Eli Lilly & Co. Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.3.5 Eli Lilly & Co. Key News & Latest Developments
7.4 Novo Nordisk A/S
7.4.1 Novo Nordisk A/S Company Summary
7.4.2 Novo Nordisk A/S Business Overview
7.4.3 Novo Nordisk A/S Insulin Biosimilars Major Product Offerings
7.4.4 Novo Nordisk A/S Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.4.5 Novo Nordisk A/S Key News & Latest Developments
7.5 Biocon
7.5.1 Biocon Company Summary
7.5.2 Biocon Business Overview
7.5.3 Biocon Insulin Biosimilars Major Product Offerings
7.5.4 Biocon Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.5.5 Biocon Key News & Latest Developments
7.6 Geropharm
7.6.1 Geropharm Company Summary
7.6.2 Geropharm Business Overview
7.6.3 Geropharm Insulin Biosimilars Major Product Offerings
7.6.4 Geropharm Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.6.5 Geropharm Key News & Latest Developments
7.7 Wockhardt
7.7.1 Wockhardt Company Summary
7.7.2 Wockhardt Business Overview
7.7.3 Wockhardt Insulin Biosimilars Major Product Offerings
7.7.4 Wockhardt Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.7.5 Wockhardt Key News & Latest Developments
7.8 Gan&Lee Pharmaceuticals
7.8.1 Gan&Lee Pharmaceuticals Company Summary
7.8.2 Gan&Lee Pharmaceuticals Business Overview
7.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Major Product Offerings
7.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.8.5 Gan&Lee Pharmaceuticals Key News & Latest Developments
7.9 The United Laboratories International
7.9.1 The United Laboratories International Company Summary
7.9.2 The United Laboratories International Business Overview
7.9.3 The United Laboratories International Insulin Biosimilars Major Product Offerings
7.9.4 The United Laboratories International Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.9.5 The United Laboratories International Key News & Latest Developments
7.10 Tonghua Dongbao Pharmaceutical
7.10.1 Tonghua Dongbao Pharmaceutical Company Summary
7.10.2 Tonghua Dongbao Pharmaceutical Business Overview
7.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Major Product Offerings
7.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales and Revenue in Global (2018-2023)
7.10.5 Tonghua Dongbao Pharmaceutical Key News & Latest Developments
8 Global Insulin Biosimilars Production Capacity, Analysis
8.1 Global Insulin Biosimilars Production Capacity, 2018-2030
8.2 Insulin Biosimilars Production Capacity of Key Manufacturers in Global Market
8.3 Global Insulin Biosimilars Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Insulin Biosimilars Supply Chain Analysis
10.1 Insulin Biosimilars Industry Value Chain
10.2 Insulin Biosimilars Upstream Market
10.3 Insulin Biosimilars Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Insulin Biosimilars Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Insulin Biosimilars in Global Market
Table 2. Top Insulin Biosimilars Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Insulin Biosimilars Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Insulin Biosimilars Revenue Share by Companies, 2018-2023
Table 5. Global Insulin Biosimilars Sales by Companies, (K Units), 2018-2023
Table 6. Global Insulin Biosimilars Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Insulin Biosimilars Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Insulin Biosimilars Product Type
Table 9. List of Global Tier 1 Insulin Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Insulin Biosimilars Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Insulin Biosimilars Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Insulin Biosimilars Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Insulin Biosimilars Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Insulin Biosimilars Sales (K Units), 2018-2023
Table 15. By Type - Global Insulin Biosimilars Sales (K Units), 2024-2030
Table 16. By Application ? Global Insulin Biosimilars Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Insulin Biosimilars Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Insulin Biosimilars Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Insulin Biosimilars Sales (K Units), 2018-2023
Table 20. By Application - Global Insulin Biosimilars Sales (K Units), 2024-2030
Table 21. By Region ? Global Insulin Biosimilars Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Insulin Biosimilars Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Insulin Biosimilars Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Insulin Biosimilars Sales (K Units), 2018-2023
Table 25. By Region - Global Insulin Biosimilars Sales (K Units), 2024-2030
Table 26. By Country - North America Insulin Biosimilars Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Insulin Biosimilars Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Insulin Biosimilars Sales, (K Units), 2018-2023
Table 29. By Country - North America Insulin Biosimilars Sales, (K Units), 2024-2030
Table 30. By Country - Europe Insulin Biosimilars Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Insulin Biosimilars Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Insulin Biosimilars Sales, (K Units), 2018-2023
Table 33. By Country - Europe Insulin Biosimilars Sales, (K Units), 2024-2030
Table 34. By Region - Asia Insulin Biosimilars Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Insulin Biosimilars Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Insulin Biosimilars Sales, (K Units), 2018-2023
Table 37. By Region - Asia Insulin Biosimilars Sales, (K Units), 2024-2030
Table 38. By Country - South America Insulin Biosimilars Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Insulin Biosimilars Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Insulin Biosimilars Sales, (K Units), 2018-2023
Table 41. By Country - South America Insulin Biosimilars Sales, (K Units), 2024-2030
Table 42. By Country - Middle East & Africa Insulin Biosimilars Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Insulin Biosimilars Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Insulin Biosimilars Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Insulin Biosimilars Sales, (K Units), 2024-2030
Table 46. Sanofi S.A. Company Summary
Table 47. Sanofi S.A. Insulin Biosimilars Product Offerings
Table 48. Sanofi S.A. Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Sanofi S.A. Key News & Latest Developments
Table 50. Boehringer Ingelheim Company Summary
Table 51. Boehringer Ingelheim Insulin Biosimilars Product Offerings
Table 52. Boehringer Ingelheim Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Boehringer Ingelheim Key News & Latest Developments
Table 54. Eli Lilly & Co. Company Summary
Table 55. Eli Lilly & Co. Insulin Biosimilars Product Offerings
Table 56. Eli Lilly & Co. Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Eli Lilly & Co. Key News & Latest Developments
Table 58. Novo Nordisk A/S Company Summary
Table 59. Novo Nordisk A/S Insulin Biosimilars Product Offerings
Table 60. Novo Nordisk A/S Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Novo Nordisk A/S Key News & Latest Developments
Table 62. Biocon Company Summary
Table 63. Biocon Insulin Biosimilars Product Offerings
Table 64. Biocon Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Biocon Key News & Latest Developments
Table 66. Geropharm Company Summary
Table 67. Geropharm Insulin Biosimilars Product Offerings
Table 68. Geropharm Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. Geropharm Key News & Latest Developments
Table 70. Wockhardt Company Summary
Table 71. Wockhardt Insulin Biosimilars Product Offerings
Table 72. Wockhardt Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Wockhardt Key News & Latest Developments
Table 74. Gan&Lee Pharmaceuticals Company Summary
Table 75. Gan&Lee Pharmaceuticals Insulin Biosimilars Product Offerings
Table 76. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Gan&Lee Pharmaceuticals Key News & Latest Developments
Table 78. The United Laboratories International Company Summary
Table 79. The United Laboratories International Insulin Biosimilars Product Offerings
Table 80. The United Laboratories International Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. The United Laboratories International Key News & Latest Developments
Table 82. Tonghua Dongbao Pharmaceutical Company Summary
Table 83. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product Offerings
Table 84. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Tonghua Dongbao Pharmaceutical Key News & Latest Developments
Table 86. Insulin Biosimilars Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Insulin Biosimilars Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Insulin Biosimilars Production by Region, 2018-2023 (K Units)
Table 89. Global Insulin Biosimilars Production by Region, 2024-2030 (K Units)
Table 90. Insulin Biosimilars Market Opportunities & Trends in Global Market
Table 91. Insulin Biosimilars Market Drivers in Global Market
Table 92. Insulin Biosimilars Market Restraints in Global Market
Table 93. Insulin Biosimilars Raw Materials
Table 94. Insulin Biosimilars Raw Materials Suppliers in Global Market
Table 95. Typical Insulin Biosimilars Downstream
Table 96. Insulin Biosimilars Downstream Clients in Global Market
Table 97. Insulin Biosimilars Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Insulin Biosimilars Segment by Type in 2022
Figure 2. Insulin Biosimilars Segment by Application in 2022
Figure 3. Global Insulin Biosimilars Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Insulin Biosimilars Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Insulin Biosimilars Revenue, 2018-2030 (US$, Mn)
Figure 7. Insulin Biosimilars Sales in Global Market: 2018-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Insulin Biosimilars Revenue in 2022
Figure 9. By Type - Global Insulin Biosimilars Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 11. By Type - Global Insulin Biosimilars Sales Market Share, 2018-2030
Figure 12. By Type - Global Insulin Biosimilars Price (USD/Unit), 2018-2030
Figure 13. By Application - Global Insulin Biosimilars Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 15. By Application - Global Insulin Biosimilars Sales Market Share, 2018-2030
Figure 16. By Application - Global Insulin Biosimilars Price (USD/Unit), 2018-2030
Figure 17. By Region - Global Insulin Biosimilars Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Insulin Biosimilars Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 20. By Region - Global Insulin Biosimilars Sales Market Share, 2018-2030
Figure 21. By Country - North America Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 22. By Country - North America Insulin Biosimilars Sales Market Share, 2018-2030
Figure 23. US Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Insulin Biosimilars Sales Market Share, 2018-2030
Figure 28. Germany Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 29. France Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Insulin Biosimilars Sales Market Share, 2018-2030
Figure 37. China Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 41. India Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 43. By Country - South America Insulin Biosimilars Sales Market Share, 2018-2030
Figure 44. Brazil Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Insulin Biosimilars Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Insulin Biosimilars Sales Market Share, 2018-2030
Figure 48. Turkey Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Insulin Biosimilars Revenue, (US$, Mn), 2018-2030
Figure 52. Global Insulin Biosimilars Production Capacity (K Units), 2018-2030
Figure 53. The Percentage of Production Insulin Biosimilars by Region, 2022 VS 2030
Figure 54. Insulin Biosimilars Industry Value Chain
Figure 55. Marketing Channels
